glp 1 agonists and depression The risk of depression, anxiety, suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy Schematic illustration of monoagonists, dual
Description
Raccah D
Biocon : Primarily involved in biosimilars and generic medications
10.1016/j.neubiorev.2022.104551 Neurosci
[DOI] [PMC free article] [PubMed] [Google Scholar] 70.Jaiswal M, Martin CL, Brown MB, Callaghan B, Albers JW, Feldman EL, et al
CNBC's Jim Cramer on Wednesday explained how GLP-1 drugs are influencing market action
What it means for consumers: It's unclear which insurance markets or patients the $149 price tag would apply to
